CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells

SIMPLE SUMMARY: Current immunotherapy for high-risk neuroblastoma patients involves treatment with anti-GD2 antibody dinutuximab, which has significantly improved the survival rate. Still, approximately half of the patients succumb to the tumor; therefore, efforts to improve their prognosis are urge...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Sanz, Paula, Hoogendijk, Arjan J., Verkuijlen, Paul J. J. H., Schornagel, Karin, van Bruggen, Robin, van den Berg, Timo K., Tytgat, Godelieve A. M., Franke, Katka, Kuijpers, Taco W., Matlung, Hanke L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428220/
https://www.ncbi.nlm.nih.gov/pubmed/34503071
http://dx.doi.org/10.3390/cancers13174261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428220/
https://www.ncbi.nlm.nih.gov/pubmed/34503071
http://dx.doi.org/10.3390/cancers13174261

Ejemplares similares